Probiotic that contributes to a healthy natural gut flora.
The ingredients that make up these probiotics have a beneficial effect on health. Here is what the documentation describes regarding the indications of the strains found in it, among these:
Lactobacillus Acidophilus LAC 361 (1.0 x 109 CFU)
Bifidobacterium Longum BB536 (0.7 x 109 CFU)
Bifidobacterium Breve M16V (0.5 x 109 CFU)
Bifidobacterium Infantis M63 (0.5 x 109 CFU)
Arabinogalactan (600 mg)
Purposes Dosages (g) Comments
Health support 1,2,13-16 1 g/day Prevention of general infections
Acute diarrhea and rotavirus 5 1 to 2 g/day
DAA 6-8
Prevention 1 g/day 2-hour interval with antibiotic
Treatment 1 g twice a day
Atopy / Allergy 3, 9-11 1 g to 5 g/day
Specific documentation to probiotic strains for children
Reduction in the number of infections (20/75 vs 33/87 control) and the duration of hospitalizations (mean 89.6 days vs 102.3 days control) by the administration of bifidobacteria (M16) in preterm infants.
1. Sato Y, Shinohara K, Shiga S, et al. Effect of administration of bifidobacterial in premature infants. Acta Neonatalogia Japonica 2003;39(2): 247.
Prevention of MRSA nosocomial infections in preterm infants. (Before: MRSA carriers 30.5% & reported infections (NTED) 9.5%; After administration of Bifido M16: Carriers 12.3% and NTED 2.2%).
2. Yamada T, Ogino S, Uchino N, et al. Infection control against methicillin resistant Staphylococcus aureus (MRSA) in neonatal intensive care unit. (Does administration of bifidobacterium prevent MRSA infection?) Acta Neonatalogia Japonica 2002;38: 294.
Reduction of allergy and atopy (eczema) in newborns. Effect of reducing allergic symptoms, especially skin symptoms (P=0.0176 for skin symptoms and P=0.0117 for the total allergic score).
3. Hattori K, Yamamoto A, Sasai M, et al. Effects of administration of bifidobacteria (M16) on fecal microflora and clinical symptoms in infants with atopic dermatitis. 2003 Jan;52(1): 20-30.
Reduction of intestinal inflammatory markers in children with cystic fibrosis or inflammatory bowel disease (IBD) (BB536).
4. Bruzzese E, Gaudiello G, Polito G et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 2004; 20: 813-819.
Documented effects of probiotics in children
Reduction in the duration of diarrhea and acceleration of rotavirus elimination in infectious gastroenteritis (day care centers).
5. Saavedra JM, Bauman NA, Oung I. et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus. Lancet 1994; 344: 1046-1049.
Reduction of antibiotic-associated diarrhea
6. D’Souza AL, Rajkumar C, Cooke J et Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhea: meta-analysis. BMJ 2002;324(7350): 1361-1369.
7. Cremonini F. Di Caro S. Nista EC et all. Meta-analysis : the effect of probiotic administration on antibiotic- associated diarrhea. Aliment Pharmacol Ther. 2002; 16: 1461-1467.
8. Charrois TL, Sandhu G, Vohra S. Probiotics. Pediatr Rev. 2006 Apr;27(4):137-9.
Prevention of allergies, eczema, and atopy
9. Furrie E. Probiotics and allergy Proc Nutr Soc (2005), 64, 465–469.
10. Bongaerts GPA, Severijnen RSVM. Preventive and curative effects of probiotics in atopic patients. Medical Hypotheses (2005) 64, 1089–1092.
11. Bengmark S, Martindale R. Prebiotics and synbiotics in clinical medicine. Nutr Clin Pract. 2005 Apr; 20(2): 244-61.
Food safety. No toxicity, no transmission of interaction, no contamination in outpatient users
12. Salminen S, von Wright. Current probiotics- safety assured? Microb Ecol Health Dis 1998; 10: 68-77.
Documented effects of arabinogalactan
Improves the gut flora (prebiotic effect) by increasing the concentration of beneficial Bifidobacteria and Lactobacilli.
Improves several functional aspects of the immune system: Activates the macrophages phagocytosis and stimulates the effectiveness of natural killer (NK) cells in the immune system. It therefore has an immunostimulant effect that adds to its prebiotic effect.
Measurable reduction of toxins level in the intestine (fecal ammonia) thus improving intestinal ecology.
Food safety. Recognized as dietary fiber by the U.S. FDA (up to 30g per day without any problems or adverse effects). Its only possible side effect is a bit of bloating in 3% of high-dose users.
- Kelly GS. Larch Arabinogalactan: Clinical Relevance of a Novel Immune- Enhancing Polysaccharide. Altern Med Rev 1999; 4(2): 96-103.
- Nantz, M.P., Painter, A.R., Parker, E.R.B., McGill, C. and Percival, S.S. Evaluation of Arabinogalactan's Effect on Human Immunity. Food Science and Human Nutrition, University of Florida, Gainesville, FL 32611.
- Robinson RR, Feirtag J, Slavin JL. Effects of dietary arabinogalactan on gastrointestinal and blood parameters in healthy human subjects. J Am Coll Nutr. 2001 Aug;20 (4): 279-85.
- https://www.arabinogalactan.com/larex/welcome/raw_materials/immunenhancer.-ParSys-0008-DownloadFile.tmp/ImmunEnhancer.pdf
Various complementary studies
- Oral Probiotics Reduce the Incidence and Severity of Necrotizing Enterocolitis in very low birth weight infants - DOI: 10.1542/peds.2004-1463 Pediatrics 2005;115;1-4 Tsu-Fuh Yeh and William Oh Hung-Chih Lin, Bai-Horng Su, An-Chyi Chen, Tsung-Wen Lin, Chang-Hai Tsai, V - https://www.pediatrics.org/cgi/content/full/115/1/
- Effects of oral administration of Bifidocbacterium longum on the development of the intestinal microflora in extremely preterm infants (comparison with Bifidocaterium breve) - Acts of Acta Neonatoligica Japonica 30, 257-263 (1994).
- Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis. - Bifidobacterium breve M-16V 1: Arerugi. 2003 Jan;52 (1): 20-30.
- Increased Poliovirus-Specific Intestinal Antibody Response Coincides with Promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: A Randomized, Double-Blind, Placebo-Controlled Trial - International Pediatric Research Foundation, Inc – 2004.
- Effects of administration of bifidobacteria in premature infants - Acts Neonatologics Japonica, 39 (2): 247, 2003.
- Infection control against methicillin resistant Staphylococcus aureus (MRSA) in neonatal intensive care unit (Does administration of Bifidobacterium prevent MRSA infection?) – Acts Neonatologics Japonica, 38, 294, 2002.
Warning: Maison Jacynthe disclaims all responsibilities. The information contained on this page does not seek to substitute a justified allopathic treatment nor to dismiss the expertise of the medical profession. It is up to each individual to take charge of their health, to inform themselves, and to make the necessary changes to improve their condition. Therapeutic supervision by a qualified healthcare professional is obviously recommended.
